Director of Pediatric Stem Cell Transplantation at Phoenix Children's Hospital

Phoenix, AZ

full-time
Inpatient and outpatient

Job Highlights

  • Area Is Warm Year-Round
  • Great Nightlife Nearby
  • Less than 1 Hour from an International Airport
  • Phoenix Children’s Hospital and the Center for Cancer and Blood Disorders seeks a Director of Pediatric Stem Cell Transplantation.

    What We're Looking for:

    • Several years of experience in the clinical care of pediatric stem cell transplant patients
    • Prior experience with academic leadership
    • Active research program with a track record of obtaining external funding

    Highlights of the Position:

    • Oversight for the Clinical and Quality programs in BMT at PCH
    • Participation in collaborative efforts with the adult BMT program at Mayo Clinic
    • Shared inpatient and night call responsibilities on the BMT service
    • Development of a translational and/or laboratory research program in a field relevant to stem cell transplantation
    • Teaching responsibilities may include medical students from the University of Arizona and Mayo Medical School, as well as Phoenix Children’s residents and Hem/Onc fellows

    About the Program:

    The pediatric BMT Program is jointly FACT accredited with the adult BMT program at Mayo Clinic Arizona and has been operational since 2003.

    • Clinical pediatric care is provided at Phoenix Children’s Hospital in a state of the art facility opened in 2009.
    • Combined Mayo Clinic adult and PCH pediatric BMT program has 10 allogeneic transplant faculty members, with four faculty members currently in Pediatrics.
    • The program currently performs approximately 40- 45 transplants annually & manages an additional 10-15 CAR-T pre-B-cell ALL patients.
    • Excellent survival rates, with the program receiving a +1 rating from the CIBMTR for the outcomes reported in Jan 2019.
    • The pediatric BMT program is a COG approved transplant site
    • The research focus of the BMT Program includes acute leukemia, myeloproliferative disorders, transplant for hemoglobinopathies and immune deficiencies, chronic GVHD, survivorship, and cellular therapies.


    Posted November 9, 2021